XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Recent Transactions, Asset Acquisition and Deconsolidation of Subsidiaries (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2023
Jul. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Mar. 31, 2023
Deconsolidation of Subsidiaries [Abstract]              
Gain on deconsolidation of subsidiaries     $ 0 $ 12,514 $ 17,354 $ 29,276  
Retained investment     $ 239,927   239,927   $ 304,317
Newly-Formed Subsidiary [Member]              
Asset Acquisition [Abstract]              
Upfront cash payment   $ 14,000          
Acquired in process research and development expense         14,000    
Newly-Formed Subsidiary [Member] | Maximum [Member]              
Asset Acquisition [Abstract]              
Milestone payment payable   280,000          
SK Biopharmaceuticals Co Ltd [Member] | Proteovant [Member]              
Deconsolidation of Subsidiaries [Abstract]              
Purchase of equity $ 47,500            
VantAI Preferred Financing [Member]              
Deconsolidation of Subsidiaries [Abstract]              
Gain on deconsolidation of subsidiaries         $ 17,400    
Retained investment   9,000          
VantAI Preferred Financing [Member] | SK, Inc. [Member]              
Deconsolidation of Subsidiaries [Abstract]              
Contributions from issuance of shares   $ 6,000